Search results
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 2 days agoThis could lead to a delay in the FDA's review, RBC's Abrahams said. "It does not appear this will...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks· 2 days agoRegeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Regeneron Misses Profit Estimates on Weaker Eylea and Dupixent Sales
US News & World Report· 2 days agoUS News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 23 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron...
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters via Yahoo Finance· 2 days agoRegeneron has been looking to switch Eylea patients to the high-dose 8 milligram version as the eye...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 4 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 2 days ago(Regeneron shares the rights to Dupixent with Sanofi.) Both should continue driving solid top-line...
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation - Regeneron...
Benzinga· 2 days agoEylea US sales fell 16% to $1.2 billion, primarily due to changing market dynamics, resulting in...
Unable to work since COVID vaccination, Gatineau man pins hopes on compensation
CBC via Yahoo News· 5 days agoA Gatineau, Que., man who developed a debilitating skin ailment after receiving a COVID-19 vaccine...
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 2 days agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...